A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.
NCT ID: NCT06414798
Last Updated: 2025-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2024-05-13
2025-02-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
NCT06673238
Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants
NCT05475821
A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
NCT07141199
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
NCT06849791
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
NCT06477926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1- ABBV-1088 Dose A
Participants will receive single dose of ABBV-1088 dose A on day 1
Drug: ABBV-1088
• Oral Capsule
Group 1- Placebo
Participants will receive single dose of placebo day 1
Drug: Placebo for ABBV-1088
• Oral Capsule
Group 2- ABBV-1088 Dose B
Participants will receive single dose of ABBV-1088 dose B on day 1
Drug: ABBV-1088
• Oral Capsule
Group 2- Placebo
Participants will receive single dose of placebo day 1
Drug: Placebo for ABBV-1088
• Oral Capsule
Group 3- ABBV-1088 Dose C
Participants will receive single dose of ABBV-1088 dose C on day 1
Drug: ABBV-1088
• Oral Capsule
Group 3- Placebo
Participants will receive single dose of placebo day 1
Drug: Placebo for ABBV-1088
• Oral Capsule
Group 4- ABBV-1088 Dose D
Participants will receive single dose of ABBV-1088 dose D on day 1
Drug: ABBV-1088
• Oral Capsule
Group 4- Placebo
Participants will receive single dose of placebo day 1
Drug: Placebo for ABBV-1088
• Oral Capsule
Group 5- ABBV-1088 Dose E
Participants will receive single dose of ABBV-1088 dose E on day 1
Drug: ABBV-1088
• Oral Capsule
Group 5- Placebo
Participants will receive single dose of placebo day 1
Drug: Placebo for ABBV-1088
• Oral Capsule
Group 6- ABBV-1088 Dose F
Participants will receive single dose of ABBV-1088 dose F on day 1
Drug: ABBV-1088
• Oral Capsule
Group 6- Placebo
Participants will receive single dose of placebo day 1
Drug: Placebo for ABBV-1088
• Oral Capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug: ABBV-1088
• Oral Capsule
Drug: Placebo for ABBV-1088
• Oral Capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG
Exclusion Criteria
* History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption \[e.g., Crohn's disease, chronic GERD, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.\].
* History of suicidal ideation within one year prior to study drug administration as evidenced by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the C-SSRS completed at Screening, or any history of suicide attempts within the last two years.
* History of any clinically significant neurological, respiratory (except mild asthma as a child), endocrine, metabolic, renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Acpru /Id# 264249
Grayslake, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M24-929
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.